Cargando…

NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities

Nicotinamide adenine dinucleotide (NAD(+)) is an essential and pleiotropic coenzyme involved not only in cellular energy metabolism, but also in cell signaling, epigenetic regulation, and post-translational protein modifications. Vascular disease risk factors are associated with aberrant NAD(+) meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdellatif, Mahmoud, Bugger, Heiko, Kroemer, Guido, Sedej, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Lipidology and Atherosclerosis 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133775/ https://www.ncbi.nlm.nih.gov/pubmed/35656147 http://dx.doi.org/10.12997/jla.2022.11.2.111

Ejemplares similares

Editorial of Special Issue “Sirtuins in Health and Disease”
por: Sedej, Simon, et al.
Publicado: (2021)

Spermidine overrides INSR (insulin receptor)-IGF1R (insulin-like growth factor 1 receptor)-mediated inhibition of autophagy in the aging heart
por: Abdellatif, Mahmoud, et al.
Publicado: (2022)

Cardiac PI3K p110α attenuation delays aging and extends lifespan
por: Abdellatif, Mahmoud, et al.
Publicado: (2022)

NAD(+) Homeostasis and NAD(+)-Consuming Enzymes: Implications for Vascular Health
por: Campagna, Roberto, et al.
Publicado: (2023)

NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential
por: Xie, Na, et al.
Publicado: (2020)

Mitochondrial Mechanisms in Diabetic Cardiomyopathy
por: Gollmer, Johannes, et al.
Publicado: (2020)

Established and Emerging Mechanisms of Diabetic Cardiomyopathy
por: Gollmer, Johannes, et al.
Publicado: (2019)

NAD(+) Metabolism and Diseases with Motor Dysfunction
por: Lundt, Samuel, et al.
Publicado: (2021)

Mitochondrial Mechanisms in Septic Cardiomyopathy
por: Cimolai, María Cecilia, et al.
Publicado: (2015)

Exercise-induced sudden cardiac death is caused by mitochondrio-nuclear translocation of AIF
por: Abdellatif, Mahmoud, et al.
Publicado: (2021)

Clinical Evidence for Targeting NAD Therapeutically
por: Radenkovic, Dina, et al.
Publicado: (2020)

Targeting Cardiovascular Risk Factors Through Dietary Adaptations and Caloric Restriction Mimetics
por: Voglhuber, Julia, et al.
Publicado: (2021)

NAD(+) metabolism-based immunoregulation and therapeutic potential
por: Fang, Jiankai, et al.
Publicado: (2023)

Calpain signaling: from biology to therapeutic opportunities in neurodegenerative disorders
por: Metwally, Elsayed, et al.
Publicado: (2023)

NAD Metabolism in Cancer Therapeutics
por: Yaku, Keisuke, et al.
Publicado: (2018)

NAD(+)-dependent mechanism of pathological axon degeneration
por: Cao, Ying, et al.
Publicado: (2022)

Mitochondrial Dysfunction and Diabetic Nephropathy: Nontraditional Therapeutic Opportunities
por: Zhang, Ping Na, et al.
Publicado: (2021)

Impact of COVID-19 on Cardiovascular Disease
por: Vosko, Ivan, et al.
Publicado: (2023)

NAD(+) Therapeutics and Skeletal Muscle Adaptation to Exercise in Humans
por: Campelj, Dean, et al.
Publicado: (2022)

Mitochondrial Dysfunction: A Basic Mechanism in Inflammation-Related Non-Communicable Diseases and Therapeutic Opportunities
por: Hernández-Aguilera, Anna, et al.
Publicado: (2013)

Balancing NAD(+) deficits with nicotinamide riboside: therapeutic possibilities and limitations
por: Cercillieux, Angelique, et al.
Publicado: (2022)

NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview
por: Pramono, Alvinsyah Adhityo, et al.
Publicado: (2020)

Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases
por: Rotllan, Noemi, et al.
Publicado: (2021)

Mass Spectrometry-Based Redox and Protein Profiling of Failing Human Hearts
por: Tomin, Tamara, et al.
Publicado: (2021)

The multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities
por: Sun, Yu, et al.
Publicado: (2022)

Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities
por: Pei, Qiying, et al.
Publicado: (2023)

Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?
por: Hölscher, Maximilian E., et al.
Publicado: (2016)

Endothelial Senescence and the Chronic Vascular Diseases: Challenges and Therapeutic Opportunities in Atherosclerosis
por: Ramírez, Rafael, et al.
Publicado: (2022)

Exploring the therapeutic space around NAD(+)
por: Houtkooper, Riekelt H., et al.
Publicado: (2012)

New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity
por: Oh, Gi-Su, et al.
Publicado: (2016)

Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders
por: Srivastava, Sarika
Publicado: (2016)

NAD+ Precursors and Intestinal Inflammation: Therapeutic Insights Involving Gut Microbiota
por: Niño-Narvión, Julia, et al.
Publicado: (2023)

RNA-Binding Proteins: Emerging Therapeutics for Vascular Dysfunction
por: Cornelius, Victoria A., et al.
Publicado: (2022)

Oxidative Stress and Vascular Dysfunction in the Retina: Therapeutic Strategies
por: Ruan, Yue, et al.
Publicado: (2020)

Proteomic Insights into Cardiac Fibrosis: From Pathophysiological Mechanisms to Therapeutic Opportunities
por: Qi, Ruiqiang, et al.
Publicado: (2022)

NAD(+) in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo
por: Wang, Xinshi, et al.
Publicado: (2021)

Vascular dysfunction and pathology: focus on mechanical forces
por: Garoffolo, Gloria, et al.
Publicado: (2021)

Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities
por: Schmidt, Marlene F., et al.
Publicado: (2021)

Enzymology of Ca(2+)-Mobilizing Second Messengers Derived from NAD: From NAD Glycohydrolases to (Dual) NADPH Oxidases
por: Guse, Andreas H.
Publicado: (2023)

Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration
por: Cimaglia, Gloria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_smirhdgfrs5vastsm2v8t04u6i